Penny Stocks To Buy For Under $1 & What To Watch Right Now. 4 cent shares to buy for less than $ 5 in December 2021
Are penny stocks worth it? To answer that question, I’ll ask this question: Do you like to make money quickly in a high-risk environment? If you said yes, then cheap stocks are worth it. In 2021 alone, thanks to penny stocks, we’ve seen some of the biggest moves in the market. For reference, we are talking about stocks below $ 5 per share.
You can do the math yourself. While I’m not advocating focusing on how much you can win versus how much you can lose during a trade, penny stocks are in a league of their own in many respects. In the blink of an eye, you’ll see some random low-priced stocks jump from under $ 5 to over $ 10 or more. This could happen for myriad reasons, but deep down, moves like this are not uncommon for penny stocks.
Today, we are seeing a handful that have not only been volatile recently, but are all trading at pennies a share. Remember, just because they trade cheaply does not mean that risk factors can be ignored. So I’ll let you decide: Are these the penny stocks to buy right now, or should I avoid them altogether?
Penny stocks to buy for less than $ 1
Gran Tierra Energy Inc.
Energy stocks remain a focus of attention as reopening efforts continue globally. While there are arguments in favor of green or renewable energy, traditional sources are being actively used right now not only to sustain economic growth, but also to help build the alternative energy ecosystem. Gran Tierra Energy falls into this category.
– 3 cent stocks to watch with bullish sentiment right now
The company specializes in the exploration and production of oil and natural gas through its portfolio of assets in South America. Colombia is where its primary production originates within a region responsible for the production that generated $ 35 million last quarter.
Gran Tierra’s recent quarterly update reported strong growth, year-over-year for the third quarter of 2021. Included in this were average total production rates that increased more than 50% compared to the third quarter of 2020 and more than 205 % from the previous quarter.
What to watch with GTE Stock
One of the things to keep in mind about GTE’s stock is that it has moved in the general direction of the overall energy market. Despite being one of the penny shares below $ 1, stocks are up more than 90% so far this year. Considering that oil and natural gas prices have recently rebounded, GTE could be in the penny stock list to watch right now.
Palatin Technologies Inc.
Unlike Gran Tierra, Palatin Technologies has seen a different move so far this year in the stock market in 2021. Even with this as the case, PTN shares are back on the watch list after just a few weeks. of great momentum. One of the initial catalysts came after the recent Palatin update by analysts at HC Wainwright. The company raised its price target to $ 5 after the most recent round of quarterly results.
One of the things to keep in mind is management’s comment on the company’s clinical process. In particular, CEO Carl Spana, Ph.D., spoke about various treatments and treatment candidates, including PL9643, PL8177, and Vyleesi. Notably, according to HC Wainwright analyst Joseph Pantginis, “PL9643 is about to begin its fundamental Phase 3 study on dry eye disease, and visibility is growing on the company’s overall differentiated melanocortin platform.” .
What to watch with PTN stocks
Meanwhile, vaccine stocks have refocused thanks to new concerns emerging from the Omicron variant. Palatin’s PL8177 was originally in development for inflammation (things like IBS, for example). However, the company announced last year that it would begin developing the candidate as a potential treatment for COVID patients. With this, PTN’s actions have been something to watch out for over the past few weeks.
Small-cap and micro-cap biotech penny stocks have been a stronger focus for traders over the past few quarters. Aside from being smaller companies in the early stages, the potential for a novel discovery is not an uncommon event. In the case of Matinas BioPharma, the company’s breakthrough came towards the end of the last quarter. He announced data in an ongoing trial of his MAT2203 for the treatment of cryptococcal meningitis. In particular, patients who completed induction with treatment showed sterility after treatment, with an overall survival of more than 95% in patients who are part of cohort 2.
– Hot Metaverse penny stocks to add to your list in December 2021
Since then, the company has been building its leadership team. The most recent addition was announced earlier this week, with a new Chief Commercial Officer on board. According to the company, the main focus of the new CBO, Thomas Hoover, will be the advancement of Matinas’ lipid nanocrystal platform.
What to do with MTNB stocks
Other than that, there are a few other things to look out for before the end of the year and early 2022. First, Matinas Cohort 3 from their MAT2203 study has enrolled the majority of patients. An assessment by the Data and Security Monitoring Board and an assessment of the cohort progression is anticipated before the end of 2021.
The company has also said it plans to meet with the FDA this month to review the data to date and discuss possible approval of the treatment as an intravenous amphotericin B lowering therapy. patients with nontuberculous mycobacterial infections. Enrollment is expected to end next quarter, with data expected during the second quarter of 2022. Finally, Matinas is conducting an in vivo efficacy study of LNC remdesivir in collaboration with the National Institute of Allergy and Infectious Diseases in cooperation with Gilead Sciences. Data is expected for this quarter.
With a host of potential events to keep track of, MTNB stocks might be one of the names you need to know right now.
Like PTN, AGRX shares have not experienced the biggest trend to date in 2021. However, the last few weeks have seen a rebound in bullish momentum. Since hitting 52-week lows of $ 0.54 in late November, AGRX shares have rallied above $ 0.60. One of the central points of focus for the market has been analyst sentiment around Agile. Of the most recent firms to cover the company this year, Oppenheimer, Royal Bank Of Canda, Maxim Group and HC Wainwright have placed Buy or equivalent ratings on AGRX. Also, all companies have price targets that range between $ 1.03 and $ 6 right now.
Agile Therapeutics is a women’s healthcare company. Its product portfolio includes platforms designed to deliver contraception without taking a daily pill. The company’s Twirla product, for example, is a transdermal patch for delivering medications through the skin. According to the company’s most recent quarterly report, Twirla’s recharge rates continue to grow at a rate of more than 80% during the third quarter.
What to watch with AGRX stocks
Considering the growth of Twirla, this product is likely to become a focus of attention during the end of the year. Earlier this quarter, the California Medicaid program, Medi-Cal, placed Twirla on the preferred drug formulary list. It secured positioning in a program that provides health care to approximately 15 million beneficiaries, according to the company. Agile explained in its Q3 update that it also started activating a brand influence program to increase product awareness.
Are Cheap Penny Stocks On Your List Right Now?
Whether you are looking for quick profits or early opportunities, penny stocks can offer many options. The main thing to remember is that there are many risks involved. In light of this, your plan and strategy should be at the forefront no matter what price of penny stocks you are looking to buy or sell.